RayKnowChina Research Map
Shortlist

Not yet recruitingCoronary heart diseaseN/A

Registered title, quoted from ClinicalTrials.gov

Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Sir Run Run Shaw Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07920055, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Prior treatment of coronary in-stent restenosis with a paclitaxel-coated balloon alone; recurrent restenosis is in the previously treated segment, including 5 mm beyond the stent edge.

    Inclusion criterion 3

  3. eGFR <30 mL/min/1.73 m² or dialysis.

    Exclusion criterion 2

    ALT or AST >3 times the upper limit of normal.

    Exclusion criterion 3

    Active bleeding, major bleeding within 3 months, or preprocedural hemoglobin <10 g/dL.

    Exclusion criterion 5

    Platelets <100,000/mm³ or INR >1.5 in the absence of anticoagulation.

    Exclusion criterion 6

  4. Pregnancy, planned pregnancy during the study, inability to use effective contraception through the 12-month visit, or breastfeeding.

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07920055, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years.
  • Stable angina, acute coronary syndrome (NSTEMI at least 7 days after onset or STEMI at least 30 days after onset), prior myocardial infarction, or documented asymptomatic myocardial ischemia.
  • Prior treatment of coronary in-stent restenosis with a paclitaxel-coated balloon alone; recurrent restenosis is in the previously treated segment, including 5 mm beyond the stent edge.
  • Quantitative coronary angiography shows diameter stenosis ≥70%, or ≥50% with evidence of myocardial ischemia.
  • Suitable for either type of coronary revascularization under study.
  • Willing to take aspirin and clopidogrel for 3 months, followed by aspirin monotherapy through study completion.
  • Willing to undergo angiographic and IVUS follow-up at 9 months and clinical follow-up at 30 days and 6, 9, and 12 months.
  • Able to understand the study, provide written informed consent, and comply with study procedures.
  • At least one recurrent target in-stent restenosis lesion requiring intervention, in one target vessel, with no more than two target lesions; any other de novo lesion requiring intervention must be >10 mm away from a target lesion.
  • Mehran type I, II, or III in-stent restenosis of a bare-metal, inert-coated, or drug-eluting stent; target reference vessel diameter 2.5-4.0 mm and each target-lesion length ≤34 mm.

Exclusion Criteria:

  • Takayasu arteritis or active vasculitis.
  • eGFR <30 mL/min/1.73 m² or dialysis.
  • ALT or AST >3 times the upper limit of normal.
  • Left ventricular ejection fraction <30%.
  • Active bleeding, major bleeding within 3 months, or preprocedural hemoglobin <10 g/dL.
  • Platelets <100,000/mm³ or INR >1.5 in the absence of anticoagulation.
  • Cardiogenic shock.
  • Concomitant disease requiring cytotoxic treatment or radiotherapy.
  • Known allergy or contraindication to aspirin, heparin, clopidogrel, sirolimus, ticagrelor, tirofiban, paclitaxel, or iopromide; or contrast allergy not manageable with prophylaxis.
  • Bleeding diathesis or a condition such as gastrointestinal ulcer that limits or prevents required antithrombotic therapy.
  • Pregnancy, planned pregnancy during the study, inability to use effective contraception through the 12-month visit, or breastfeeding.
  • Critical illness or life expectancy ≤1 year.
  • Participation in another interventional study.
  • Investigator judgment that the participant is unsuitable for the study.
  • Three-vessel disease requiring treatment (all three major epicardial vessels with ≥70% stenosis and ischemia) or left main coronary disease.
  • More than three lesions expected to require treatment overall, or more than two lesions requiring treatment in any coronary artery.
  • Target lesion with residual stenosis >30%, TIMI flow <3, or type C or worse dissection after predilatation.
  • Target lesion with tortuosity, severe calcification, or angulation expected to prevent passage of the study balloon.
  • Thrombus-containing target lesion.
  • Prior coronary artery bypass grafting.

Quoted from ClinicalTrials.gov, NCT07920055, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07920055, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07920055